SCHEMBL2834202

SCHEMBL2834202

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OCC2CCO2)cc1F)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.41
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PRKAG3 Q9UGI9 1/20 0.37
PRKAG2 Q9UGJ0 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
PARP10 Q53GL7 2/20 0.35
PARP15 Q460N3 1/20 0.35
SCN9A Q15858 4/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
GRM5 P41594 1/20 0.34
SLC6A3 Q01959 4/20 0.34
SCN5A Q14524 1/20 0.34
CNR2 P34972 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834216 0.96 RAB9A (0.40) S1PR3SCN9ANPC1RAB9ACASP3
SCHEMBL2836317 0.83 S1PR3 (0.40) S1PR3SLC6A3
SCHEMBL2836530 0.83 FFAR1 (0.36) S1PR3PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL2836695 0.82 S1PR3 (0.41) S1PR3SCN9ASCN5ACNR2
SCHEMBL2837636 0.79 RAB9A (0.39) NPC1RAB9ACASP3SENP7GRM5
SCHEMBL2834826 0.78 AAK1 (0.45) S1PR3NPC1RAB9AALDH1A1MAPT
SCHEMBL2838253 0.76 S1PR3 (0.46) S1PR3PARP10PARP15CNR2
SCHEMBL2835273 0.76 S1PR3 (0.43) S1PR3MCHR1
SCHEMBL2837574 0.73 S1PR3 (0.50) S1PR3KDM4EALDH1A1MAPT
SCHEMBL2836947 0.71 S1PR3 (0.40) S1PR3SLC6A3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885PRKAB2 4571/4885PRKAG1 3964/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885PRKAB2 4571/4885PRKAG1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.